Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.
Multimodal Research Area, Bambino Gesù Children Hospital IRCCS, Rome, Italy.
PLoS One. 2023 Sep 1;18(9):e0291120. doi: 10.1371/journal.pone.0291120. eCollection 2023.
Detection of subgenomic (sg) SARS-CoV-2 RNAs are frequently used as a correlate of viral infectiousness, but few data about correlation between sg load and viable virus are available. Here, we defined concordance between culture isolation and E and N sgRNA quantification by ddPCR assays in 51 nasopharyngeal swabs collected from SARS-CoV-2 positive hospitalized patients. Among the 51 samples, 14 were SARS-CoV-2 culture-positive and 37 were negative. According to culture results, the sensitivity and specificity of E and N sgRNA assays were 100% and 100%, and 84% and 86%, respectively. ROC analysis showed that the best E and N cut-offs to predict positive culture isolation were 32 and 161 copies/mL respectively, with an AUC (95% CI) of 0.96 (0.91-1.00) and 0.96 (0.92-1.00), and a diagnostic accuracy of 88% and 92%, respectively. Even if no significant correlations were observed between sgRNA amount and clinical presentation, a higher number of moderate/severe cases and lower number of days from symptoms onset characterized patients with sgRNA equal to or higher than sgRNA cut-offs. Overall, this study suggests that SARS-CoV-2 sgRNA quantification could be helpful to estimate the replicative activity of SARS-CoV-2 and can represent a valid surrogate marker to efficiently recognize patients with active infection. The inclusion of this assay in available SARS-CoV-2 diagnostics procedure might help in optimizing fragile patients monitoring and management.
亚基因组(sg)SARS-CoV-2 RNA 的检测常被用作病毒传染性的相关指标,但关于 sg 载量与活病毒之间的相关性的数据较少。在此,我们通过 ddPCR 检测法定义了 51 份来自 SARS-CoV-2 阳性住院患者的鼻咽拭子中培养分离物与 E 和 N sgRNA 定量之间的一致性。在 51 个样本中,有 14 个样本培养分离物为 SARS-CoV-2 阳性,37 个为阴性。根据培养结果,E 和 N sgRNA 检测的灵敏度和特异性分别为 100%和 100%,84%和 86%。ROC 分析表明,预测阳性培养分离的最佳 E 和 N 截止值分别为 32 和 161 拷贝/ml,AUC(95%CI)分别为 0.96(0.91-1.00)和 0.96(0.92-1.00),诊断准确性分别为 88%和 92%。尽管 sgRNA 数量与临床表现之间没有观察到显著相关性,但 sgRNA 等于或高于 sgRNA 截止值的患者中,中度/重度病例数量较高,症状出现后天数较低。总的来说,这项研究表明,SARS-CoV-2 sgRNA 定量可以帮助评估 SARS-CoV-2 的复制活性,并可以作为有效识别活跃感染患者的替代标志物。在现有的 SARS-CoV-2 诊断程序中纳入该检测可能有助于优化对脆弱患者的监测和管理。